お知らせ • May 02
EHAVE, Inc. announced delayed 20-F filing On 05/01/2026, EHAVE, Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC. お知らせ • Sep 09
EHAVE, Inc. has filed a Follow-on Equity Offering in the amount of $200 million. EHAVE, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 2,000,000,000
Price\Range: $0.0005 to $0.1
Discount Per Security: $0 お知らせ • Dec 17
FDA Grants EHAVE, Inc. Consent to Proceed with Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder Ehave, Inc. announced that it received confirmation from the U.S. Food and Drug Administration that its review of Investigational New Drug application is complete. The FDA authorized Ehave to proceed with its clinical study, "An open label study of electrographic responses pre, during and post, a low dose, weekly intravenous ketamine infusion for 4 weeks, in a study population with major depression disorder submitted under section 505 of the Federal Food, Drug, and Cosmetic Act for Ketamine HCl. The objective of this study is to characterize the change in EEG response of patients with MDD, during and 4 weeks after a course of IV ketamine infusions. The clinical study includes 35 participants with Major Depression Disorder. It will include subjects with an inadequate response to at least two FDA-approved antidepressant therapies, including the current course of antidepressant therapy, at a sufficient dose and duration for the current episode. An electroencephalography machine measures the brain’s activity at baseline and after four weekly low-dose IV ketamine study treatments. The purpose of the study is to learn about the neurological responses seen on EEGs of participants receiving low-dose IV ketamine therapy. Dr. Jeffrey Kamlet and Tristar Wellness will complete the study. Dr. Kamlet has served as the principal investigator on more than 20 major pharmaceutical trials. More than 264 million people across the globe suffer from depression. As a pervasive and often chronic health condition, depression is a global health burden and a significant source of disability. While depression might be considered a non-fatal health burden, severe depressive symptoms can lead to suicide, which is the second most common cause of death in people aged 15-29 years. Common treatments for depression include pharmacological interventions such as selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors and tricyclic antidepressants and psychotherapy; however, the efficacy of these interventions often fails in severe cases. Ketamine is a dissociative anesthetic, used most frequently in veterinary medicine and pediatrics, that has been repurposed as an off-label analgesic and antidepressant. Extensive investigation of its rapid antidepressive effects have been a breakthrough offering a potential reprieve to those suffering from MDD. Ketamine has also been shown to reduce suicidal ideation in depressed patients at risk for suicide. Similarly, the administration of ketamine was effective at reducing depressive symptoms, acute suicidal behavior, and mood lability in the youth with treatment-resistant depression and bipolar disease. Intranasal esketamine is the only form of ketamine that has been FDA-approved as a treatment for TRD. However, clinical research and real-world feasibility have established significant drawbacks to intranasal ketamine, including patient discomfort with administration, greater risk of diversion to the illicit market, and potentially serious adverse reactions. Intravenous use of racemic ketamine is the more established route of administration as it has long been used as an anesthetic at much higher doses. Ehave management believes intravenous administration of ketamine includes benefits which include greater dose control and reduced cost of drug acquisition. This belief is the fundamental premise that has led to many dedicated outpatient clinics offering intravenous ketamine therapy for MDD across the United States. お知らせ • May 03
EHAVE, Inc. announced delayed 20-F filing On 05/02/2022, EHAVE, Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC. お知らせ • Apr 20
Ehave, Inc. Announces MetaHealthU Will Enter The Market With A Focus On HPPD Ehave, Inc. announced its MetaHealthU mobile application platform will focus on determining the cause and finding a possible cure for hallucinogen-persisting perception disorder (HPPD). Ehave has pioneered HPPD research efforts by launching a series of studies through its partnership with the University of Melbourne to gather data and bio-markers to target the condition. HPPD, (HPPD) or “flashbacks” is the only recognized long-term complication of hallucinogen use. It can cause a person to keep reliving the visual element of an experience caused by hallucinogenic drugs. As psychedelics become more widely accepted, the data and biomarkers from Ehave’s MetaHealthU will enhance research into HPPD, which will assist medical and mental health professionals diagnose if an individual is genetically predisposed to suffer from the condition. MetaHealthU is a mobile application platform that empowers individuals to take complete control of their health and their healthcare data. One component of MetaHealthU is its digital wallet connectivity with blockchain, which enables users to bundle and share their health records in a secure and seamless way. Ehave chose blockchain for its MetaHealthU platform since it increases trust, security, transparency, and the traceability of data shared across a business network — and delivers cost savings with new efficiencies. Ehave has partnered with BurstIQ, the leading provider of blockchain-based data solutions for the healthcare industry, to use its privacy-protecting technology to protect the personal information of MetaHealthU users. With MetaHealthU, users can securely track their health data from wearables, Electronic Health Records Systems (EHRs), Doctors and Medical Labs. It includes a “digital file cabinet” for medical records, which is ideal for research into HPPD. Users can log into their patient portals on various healthcare systems and medical labs and download their medical records in the digital file cabinet, which empowers individuals to take complete control of their health and their healthcare data. As Ehave progresses in its partnership with the University of Melbourne, the Company plans to create bio lines and a testing revenue model, as well as screening products based on MetaHealthU that are capable of indicating HPPD. Currently, researchers at the University of Melbourne have completed the necessary documents required for university ethics approval for online study of HPPD. The pilot study will begin sometime late in the second quarter, or the beginning of the third quarter. The researchers have also submitted a full ethics application, and are awaiting a decision on minimal risk accreditation. They have received preliminary approval for the pilot project to be considered “low or negligible risk,” and received ethics board review feedback on the submission seeking clarification on the role of funders regarding data, as well as minor clarifications on surveys/tasks being used. Individuals with HPPD have recurring visual disturbances that only recall the part of the psychedelic experience that involved visions, which can cause anxiety and affect a person’s vision. HPPD is most commonly caused by LSD and Mushrooms, but also can be caused by MDMA, Cannabis, and even SSRIs. As many as 5% of LSD users report some version of HPPD and serious cases could be as frequent as 1 in every 100 users of psychedelics. The market for an HPPD cure extends far beyond simple psychedelics. お知らせ • Feb 10
EHAVE, Inc. (OTCPK:EHVV.F) acquired Rejuv IV Inc. EHAVE, Inc. (OTCPK:EHVV.F) acquired Rejuv IV Inc. on February 9, 2022. Rejuv IV will become KetaDASH, a wholly owned subsidiary of Ehave, Inc.
EHAVE, Inc. (OTCPK:EHVV.F) completed the acquisition of Rejuv IV Inc. on February 9, 2022 お知らせ • Jun 03
Ehave Expands Dashboard Capabilities to Include Decentralized Trials and Virtual Studies Ehave, Inc. announced the expansion of its Dashboard capabilities to include data management platform technologies which allow digitally captured information, like electronic health records (EHRs) to be shared. Under the terms of the licensing agreement with Health Wizz, Ehave will offer its dashboard users medical records management and retrieval through a dedicated instance on the AWS (Amazon Web Services) platform. This takes the Ehave dashboard to a new level by providing a HIPAA compliant, decentralized mobile platform that enables people to aggregate, organize and share personal medical health records securely and efficiently. Ehave will be able to engage with patients remotely through a series of milestones on their phones. Health Wizz deliverables to Ehave include an Ehave branded mobile app on the App Stores, as well as a HIPAA compliant dedicated backend and web portal to engage with patients. The Ehave partnership with Health Wizz will enable people to download, aggregate, and standardize all of their health records on their mobile phones. This advanced technology will provide data integrity and patient privacy while allowing people to share their medical data with medical providers, research organizations, and pharmaceutical companies conducting clinical trials. The Health Wizz mobile platform leverages blockchain technology to provide consumers with the tools they need to aggregate, manage and share their medical data with stakeholders, including research organizations and pharmaceutical companies, all while ensuring data integrity and protecting patient's privacy. お知らせ • May 02
EHAVE, Inc. announced delayed 20-F filing On 04/30/2021, EHAVE, Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC. お知らせ • Mar 05
Ehave Inc. Files for KetaDash Trademark Ehave, Inc. announced that it has filed application #90549575 on February 26, 2021 with the United States Patent and Trademark Office (USPTO) for a trademark on its KetaDASH brand name. The application has been accepted by the USPTO and will be assigned to an examining attorney. Ehave recently announced plans to launch open testing of its KetaDASH ketamine IV therapy in the second quarter using advanced vein technology. On March 1, 2021, Ehave successfully filed its application to uplist its shares on the OTCQB market. The USPTO is the federal agency for granting U.S. patents and registering trademarks, and it registers trademarks based on the commerce clause of the Constitution (Article I, Section 8, Clause 3). The KetaDASH www.ketadash.com platform allows licensed ketamine clinics and patients who have been prescribed ketamine by a physician to administer the treatment at home intravenously. KetaDASH is a personalized mental care platform designed to instantly connect patients with highly skilled nurses to provide ketamine therapy at home under expert supervision. The platform has been strategically designed as a smart and intuitive dashboard from where patients and their associated nurses can get detailed insight on treatments. KetaDASH will soon be available on the App Store and Google Play Store. お知らせ • Feb 27
Ehave, Inc. Plans to Launch KetaDASH Test in Second Quarter 2021 Ehave, Inc. announced plans to launch open testing of its KetaDASH ketamine IV therapy in the second quarter using advanced vein technology. KetaDASH is a personalized mental care platform designed to instantly connect patients with highly skilled nurses to provide ketamine therapy at home under expert supervision. The platform has been strategically designed as a smart and intuitive dashboard from where patients and their associated nurses can get detailed insight on treatments. KetaDASH will soon be available on the App Store and Google Play Store. Ehave has also secured an umbrella policy to cover liability and malpractice insurance on each home delivery service. Clinicians will only need to fulfill each order without need to add additional cost to their bottom line. The KetaDASH platform allows licensed ketamine clinics and patients who have been prescribed ketamine by a physician to administer the treatment at home intravenously. This gives the clinic an opportunity to increase revenues by treating patients who are unable to come to their office. KetaDASH has also expanded the opportunity for the clinician to increase revenue by servicing all incoming orders with a full blanket of insurance coverage. This liability insurance will be provided by Ehave, so the servicing clinic will not have to add additional insurance coverage. Clinicians will also be provided the latest infrared technology to improve the efficacy of venous access, which is crucial in the industry. As a means of to improving the efficacy of venous access, KetaDASH has signed an agreement with Vein-Eye Carry to use its infrared imaging technology. Everyday there are 30 million to 40 million vein punctures worldwide and approximately 3 million in the USA. Delays in treatment can occur in approximately 25% of all patients due to the inability to establish IV access, or "find a vein," as it is more commonly referred to. One in three attempts to establish IV access result in failure in adults, and one in two attempts fail in pediatrics. With critically ill patients the failure rate of vein punctures ranges from 10% to 40% where vein punctures are more difficult. お知らせ • Feb 02
Ehave, Inc. Couples KetaDASH with Digital Therapeutics Expertise to Combat Clinical Depression Ehave, Inc. is announcing plans to roll out its ketamine home delivery platform known as KetaDASH. The backbone for KetaDASH will be Ehave’s expertise in the area of digital therapeutics, which has been developed through years of testing in the area of mental healthcare. Ehave’s digital therapeutics insight will empower patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. After years of continued work to develop its proprietary digital therapeutics technology, Ehave is ahead of other psychedelic companies that are in the process of building integrated technical platforms and comprehensive toolsets to deliver psychedelic inspired medicines and experiential therapies combined with digital therapeutics. Research has indicated ketamine is the most significant new development in psychiatry given its high efficacy for treating major depression. Many studies have shown that in addition to depression, ketamine could be a potential treatment for obsessive-compulsive disorder, post-traumatic stress disorder, and several other treatment-refractory neuropsychiatric disorders. Ketamine was originally approved as an anesthetic and safe alternative to phencyclidine by the US Food and Drug Administration (FDA) in 1970. In 2000, researchers concluded that ketamine is a fast-acting that also provides long-term effects. お知らせ • Jan 28
Ehave, Inc. Announces to expand Ketadash to Palliative Care Ehave, Inc. announced it is exploring how palliative patients could benefit from its Ketamine home delivery platform, KetaDASH. Ehave’s Advanced Approach to Palliative Care for Cancer Patients. Palliative care refers to specialized medical care for those patients who are suffering from a serious illness According to the World Health Organization (WHO), palliative care is an approach that improves the quality of life of patients and their families facing the problem associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual. In many studies, it has been observed that the diagnosis of cancer causes a serious impact on the patients' minds, often leading many of them to develop serious mental conditions like severe depression and anxiety. お知らせ • Jan 24
EHAVE, Inc. (OTCPK:EHVV.F) completed the acquisition of Tangible and Intangible Assets of CureDash, Inc. EHAVE, Inc. (OTCPK:EHVV.F) entered into an asset purchase agreement to acquire Tangible and Intangible Assets of CureDash, Inc. on December 16, 2020.
EHAVE, Inc. (OTCPK:EHVV.F) completed the acquisition of Tangible and Intangible Assets of CureDash, Inc. on January 22, 2021. The CureDash assets include an IV delivery platform that will become the backbone of KetaDASH. お知らせ • Jan 22
Ehave Revolutionizes Patient Medical Records for Psychedelic Mental Health Ehave, Inc. announced the availability of a breakthrough comprehensive solution for medical record exchange as the first plugin to its Ehave Dashboard. The medical record exchange plugin will allow patients to own their own healthcare records and work more closely with medical professionals and psychedelic researchers to target conditions that are poorly addressed by the healthcare system today, such as chronic diseases, treatment-resistant depression, and neurological disorders. The medical record exchange plugin on Ehave's Dashboard could also potentially be of interest to pharmaceutical companies by changing the way they develop or market products. Since major pharmaceutical companies don’t develop drugs for them, the Ehave Dashboard could potentially aggregate data from this patient population and provide that data to drug developers for clinical trials. This data could also help insurers’ route patients to the treatment providers who can help them the most. Collecting real-world evidence in support of patient outcomes and economic value has long been a challenge for those seeking market access for their products. The medical record exchange plugin on Ehave's Dashboard could offer insights into how medicine is consumed and real-time data on its impact. Companion sensors could notify a drug company how patients react to their medication, which could influence R&D, or indicate when a relatively low-grade therapy is not working. お知らせ • Jan 12
Ehave, Inc. Forms Partnership with Cognitive Apps to Introduce Revolutionary AI Voice Assistant that will Revolutionize Mental Health in Psychedelic Sector Ehave, Inc. announced it has licensed revolutionary AI to unlock the human voice as a meaningful measurement of health. The AI technology is a mobile app that is a mental health monitoring tool based on voice tone and context analysis. Characteristics of the human voice, such as voice tone and context analysis, are what medicine labels vocal biomarkers. Vocal biomarkers reveal vital information about an individual’s health, as well as help in detecting serious diseases and health risks. They are medical signs coming from features in the human voice, similar to other biomarkers like pulse and blood pressure. Capturing and analyzing subtle changes in the human voice, like pitch, intensity, vocal tract coordination, jitters, shimmers, tremors, and pauses, creates a range of health measurements that provide a more complete picture of an individual's health in seconds. The AI app is capable of analyzing the human voice to identify dishonest answers to questions about behavior. This will assure researchers and medical professionals get honest, concrete answers. AI voice technology can aid with early detection and prognosis of potential mental health problems, like bipolar disorder and depression, as well as provide a more complete picture of health. Psychedelic researchers or medical providers using the Ehave dashboard, or collaborating with its dashboard, will be able to use its AI technology to intake and run their clinical trials and or research. お知らせ • Dec 10
Ehave, Inc. and Identity Key Announce Partnership for Blockchain Based Identity Verification Software for the Medical Industry EHAVE, Inc. announced that it has entered into a partnership with Identity Key to provide blockchain based identity verification software for the medical industry. The Agreement calls for the Identity Based Plug-in to be integrated into Ehave’s Dashboard. Ehave will generate royalty revenue based on sales of identity verification software from Identity Key. Ehave currently has products in development that focus on telemedicine, providing medical data, and regulated substance research for mental health. Identity Key is a software company that focuses on creating verifiable credentials for users through the blockchain. Blockchain technology is creating huge opportunities for patients, doctors, and researchers to access data in new ways with audit trails and verifiable authentication. お知らせ • Dec 06
Ehave, Inc. Dashboard Enters Final Simulations of Clinical Trials with the Hospital for Sick Children EHAVE, Inc. announced plans to initiate final simulations of Clinical Trials on its Dashboard with The Hospital for Sick Children (SickKids). The final simulations phase of the clinical trials for the Ehave Dashboard involves SickKids processing data through the dashboard and clinicians utilizing Ehave's proprietary AI technology. The Ehave Dashboard is a data driven platform that has been strategically developed to provide better communication among medical practitioners and health care providers. The cloud based platform can deliver critical features and capabilities to healthcare providers, all while enabling seamless integrations with everything from electronic health records (EHRs) to telehealth providers. The aggregation of data and information into one application has proven effective in streamlining the health process for both patients and providers. The AI powering the Ehave Dashboard is designed to alter itself when it accesses new data. By accessing the new data, the dashboard “learns.” collaboration with clinicians and researchers typically prompts this ability to improve using an objective of minimal error. This allows the system to comprehend which efforts are successful and increase the likelihood of using similar steps in the future. お知らせ • Nov 10
Ehave, Inc. Partners with Burstiq to Deploy its Ehave Dashboard over Burstiq's Blockchain Network Ehave, Inc. announced it has partnered with BurstIQ to deploy its Ehave Dashboard over BurstIQ's blockchain network to leading healthcare organizations in the United States. The Ehave Dashboard is a data driven platform that has been strategically developed to provide better communication among medical practitioners and health care providers. The cloud based platform can deliver critical features and capabilities to healthcare providers, all while enabling seamless integrations with everything from electronic health records (EHRs) to telehealth providers. The aggregation of data and information into one application has proven effective in streamlining the health process for both patients and providers. As a result of the strategic partnership with BurstIQ to further develop the blockchain capabilities of its platform, the Ehave Dashboard has the ability to segment data on-chain, which will allow developers, clinicians, researchers, doctors, hospitals, universities and, ultimately, prescribers of Psychedelic therapy, to provide life-changing solutions to patients. The Ehave Dashboard has been developed through years of testing with mental healthcare professionals at one of Canada’s large hospitals, The Hospital for Sick Children in Ontario. In addition to providing better outcomes, the proprietary platform allows individuals to take control of their physical and mental health by enabling them to carry their medical records with them wherever they go. BurstIQ is a HIPAA and GDPR compliant global data platform, and the industry’s only Big Data blockchain that keeps data on chain and safe in the cloud. Protecting patient data and Electronic Health Records is of utmost importance to healthcare providers. The U.S. Cybersecurity and Infrastructure Security Agency (CISA), with the Federal Bureau of Investigation and the Department of Health and Human Services, have issued a cybersecurity advisory to the U.S. healthcare sector regarding a concerted effort to compromise and take hostage the computer systems of healthcare providers.i Several healthcare companies have been hit with litigation as patient records were compromised. The Office for Civil Rights reached a settlement with the city of New Haven, Connecticut, including a $202,400 civil monetary penalty and a corrective action plan, following a breach to the protected health information of just 498 patients caused by a 2017 HIPAA violation.ii Patients whose medical records were improperly accessed by a former Mayo Clinic employee are attempting to mount a class-action lawsuit against the health care provider for failing to protect their sensitive personal data.iiiRiverside Psychiatric Medical Group settles with HHS OCR to resolve a potential HIPAA Right of Access violation. Missouri-based Saint Francis Healthcare System has reached a proposed $350,000 lawsuit settlement with the patients impacted by a ransomware attack on Ferguson Medical Group.iv These are only a few examples of the seriousness of protecting Electronic Health Records. お知らせ • Jun 18
EHAVE, Inc. Auditor Raises 'Going Concern' Doubt EHAVE, Inc. filed its 20-F on Jun 12, 2020 for the period ending Dec 31, 2019. In this report its auditor, Turner, Stone & Company, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.